NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
Clinical Trials
10 trialsNCT01497444 2020-02-06
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT01833546 2018-10-15
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03098160 2017-10-30
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Threshold Pharmaceuticals
Phase 1 Unknown
NCT01485042 2017-09-01
PATH
Duke University
Phase 1 Completed
NCT02020226 2016-06-02
A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1 Unknown
NCT02598687 2016-04-21
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.
Maastricht Radiation Oncology
Phase 1 Withdrawn
NCT01149915 2015-05-07
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Threshold Pharmaceuticals
Phase 1 Completed
NCT01381822 2014-04-21
TH-CR-410
Threshold Pharmaceuticals
Phase 1 Unknown
NCT00495144 2012-07-27
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1 Completed